| 8.82 0.02 (0.23%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.62 | 1-year : | 11.42 |
| Resists | First : | 9.1 | Second : | 9.77 |
| Pivot price | 9.11  |
|||
| Supports | First : | 8 | Second : | 6.65 |
| MAs | MA(5) : | 8.96 |
MA(20) : | 9.11 |
| MA(100) : | 8.51 |
MA(250) : | 10.16 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 25.2 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 14.86 | Low : | 7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BBOT ] has closed above bottom band by 17.7%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.91 - 8.95 | 8.95 - 8.99 |
| Low: | 8.43 - 8.48 | 8.48 - 8.52 |
| Close: | 8.74 - 8.82 | 8.82 - 8.89 |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Tue, 01 Sep 2026
BridgeBio Oncology (Nasdaq: BBOT) lines up new stock and debt sale program plus an at-the-market share facility - stocktitan.net
Tue, 01 Sep 2026
BridgeBio Oncology (Nasdaq: BBOT) sets resale plan but gets cash only if $8.37M in options are exercised - stocktitan.net
Tue, 01 Sep 2026
Three healthcare talks from BridgeBio Oncology will stream online in September - stocktitan.net
Fri, 28 Aug 2026
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
Wed, 12 Aug 2026
BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.67, Implies 168% Upside - TradingView
Tue, 11 Aug 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 27 (%) |
| Held by Institutions | 70.9 (%) |
| Shares Short | 5,830 (K) |
| Shares Short P.Month | 5,210 (K) |
| EPS | -2.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.1 % |
| Return on Equity (ttm) | -82 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -151 (M) |
| Levered Free Cash Flow | -90 (M) |
| PE Ratio | -3.89 |
| PEG Ratio | 0 |
| Price to Book value | 2.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|